Maintenance Teclistamab With or Without Lenalidomide Is Safe, Active in Newly Diagnosed Myeloma
Maintenance therapy with teclistamab with or without lenalidomide was safe and efficacious in newly diagnosed multiple myeloma.
Related Articles
Tamoxifen Reduces Ipsilateral Breast Recurrence in Good-Risk Ductal CIS
Tamoxifen reduced the risk of invasive ipsilateral breast recurrence in patients with good-risk ductal carcinoma in situ.
Anitocabtagene Autoleucel Elicits Deep Responses in Relapsed/Refractory Multiple Myeloma
Anito-cel elicited an ORR of 97% with acceptable safety in patients with relapsed or refractory multiple myeloma.
Melanocytic neoplasms in neurofibromatosis type 1: a systematic review
Our findings suggest that NF1 individuals may have a higher risk for developing melanomas and tend to have thicker melanomas and worse survival compared to…
Donate to Moffitt Cancer Center
Cancer touches all of us. Our mission – to contribute to the prevention and cure of cancer – depends on your support. There are many…
Thousands of women with breast cancer may not need ANY treatment
A breast cancer diagnosis is almost always followed by invasive biopsies, surgery, radiotherapy, chemotherapy and hormone treatments. But could all that be set to change?
Cilta-Cel Improves MRD-Negativity Rates in Lenalidomide-Refractory Myeloma
Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.
EnVision Summit
EnVision Summit is a medical education conference designed by women physicians for continuing medical education in ophthalmology and optometry.
The Rapidly Evolving Treatment Landscape in PIK3CA-mutated HR+ HER2- Breast Cancer
Panelists discuss how the evolving landscape of targeted therapies for PIK3CA-mutated HR+ HER2- breast cancer, including the approval of inavolisib and the growing importance of…
Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells
Oncogene – PRMT5-regulated splicing of DNA repair genes drives chemoresistance in breast cancer stem cells
